Login to Your Account

FDA Delivers CRL for Pfizer's Rare Disease Drug Vyndaqel

By Karen Pihl-Carey
Staff Writer

Wednesday, June 20, 2012
Asking for a second efficacy study, the FDA issued a complete response letter (CRL) for Pfizer Inc.'s new drug application for tafamidis meglumine to treat the orphan indication of transthyretin familial amyloid polyneuropathy (TTR-FAP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription